Nicotinamide adenine dinucleotide. NAD+. The cofactor that participates in roughly five hundred enzymatic reactions, sits at the center of cellular energy production, and serves as the substrate for the sirtuin family of regulatory proteins that the longevity field has been chasing for two decades. The molecule is real. The biology is real. The decline of NAD+ with age, demonstrated in tissue samples and in serum across populations, is real. What follows from those facts to "you should buy a six-hundred-dollar IV bag every two weeks" is not a straight line, and the honest read is that the line bends in places the consumer-facing marketing does not show.
The work most often cited in the consumer space comes out of the Imai and Sinclair labs, both of which have been productive on the NAD+-sirtuin axis since the mid-2000s. The mechanistic rodent and cell-culture story is genuinely interesting: restoring NAD+ in aged tissue restores certain cellular functions toward a younger phenotype, and the downstream sirtuin activation produces measurable improvements in mitochondrial function, DNA repair, and metabolic flexibility. The translational human work has not, as of this writing, demonstrated effect sizes in healthy adults that match the rodent-tissue findings. That is the gap the field is currently working through.
What an NAD+ infusion actually does
An IV infusion of NAD+ — typically 250 to 1,000 milligrams over two to four hours — raises plasma NAD+ levels measurably during the infusion and for hours afterward. The intracellular NAD+ rise, which is the metabolically meaningful number, is more variable. The transport of NAD+ across cell membranes is mediated by specific transporters and conversion pathways, not by simple diffusion, which is why an enormous bolus in plasma does not produce a proportional rise in tissue NAD+.
What members feel during the infusion, almost universally, is the side-effect profile rather than the mechanism — flushing, nausea, mild chest tightness, and a sensation of "warmth" that the infusion staff slow the drip rate to manage. Those symptoms are mostly the consequence of vasodilation and methylation cofactor depletion during the infusion. They subside after.
What members report in the days after the infusion is less consistent. Some describe improved energy, mental clarity, and exercise performance. Others describe nothing. The honest read of the small placebo-controlled human studies is that the subjective effect is real for some members and absent for others, and the responder profile is not yet predictable from baseline biomarkers.
What is settled, what is plausible
What is settled: NAD+ supplementation, in oral or IV form, raises serum NAD+. Pellagra and other clinical NAD+ deficiency states respond to repletion. Specific medical applications — chemotherapy-induced peripheral neuropathy, certain neurodegenerative conditions, alcohol-use-disorder withdrawal protocols — have early-stage clinical support. None of those are why most members come.
What is plausible but not yet settled: NAD+ supplementation in healthy older adults produces modest improvements in muscle function, exercise performance, and certain metabolic markers in the smaller human trials. The effect sizes are small. The placebo arms have, in several trials, performed better than expected, narrowing the apparent benefit. The work continues; we read it without claiming it has finished.
What is over-marketed: the framing of NAD+ infusions as "anti-aging" interventions with quantifiable longevity payoffs. The studies that support that framing in their entirety do not exist. They may exist in five years; we are not opposed to the molecule. We are opposed to selling members a six-hundred-dollar drip on the promise of an outcome the data do not yet underwrite.
Oral precursors and the shorter conversation
The competing intervention to the IV is oral supplementation with NAD+ precursors — primarily nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). These compounds are absorbed orally, raise serum NAD+ at lower magnitudes than the IV, and avoid the infusion side-effect profile entirely. The trial work on these precursors is more mature than the IV work; the ChromaDex-funded NR trials produced consistent serum-NAD+ rises and modest improvements in inflammatory markers over weeks of dosing. NMN trials have generally shown similar effects.
The honest comparison is that for healthy members interested in raising NAD+, oral precursors at sustained daily doses are the more evidence-grounded intervention, and they are cheaper by an order of magnitude. The case for the IV is narrower — specific clinical indications, post-event recovery, or a member whose oral absorption is impaired. We do not run our floor on the assumption that every member benefits equally from every modality.
How we use it
Our IV suite offers NAD+ as a quarterly modality for two specific populations. The first is post-event recovery: members emerging from a viral illness, post-surgical convalescence, or significant athletic stress where the underlying mitochondrial demand is acute. The infusion is dosed at 500 to 750 milligrams over three to four hours, slow drip, with vitamin C and magnesium added per individualized protocol. The clinical observation, reproducible across our member base, is that recovery from acute physiological stress accelerates measurably with the infusion. The mechanism is plausible; the effect size in our population is small but consistent.
The second is the cognitive-demand cohort — members in their fifties and sixties whose work is intellectually demanding, whose subjective clarity has begun to slip from baseline, and who have been screened for the underlying causes (sleep, thyroid, B12, depression) that more often explain the symptom. For this cohort, we run NAD+ as part of a quarterly protocol that includes cognitive testing, repeat lab work, and an honest conversation about which interventions in the stack are doing the work. The infusion is one input; we never present it as the input.
We do not run NAD+ as a stand-alone "youth IV" with marketing language we cannot defend. We do not run it monthly for healthy members with no specific indication. We do not run it as a stand-alone wellness service for non-members; the modality only makes sense inside a programmed clinical context.
Side-effect math
Acute side effects are dose- and rate-dependent. Slow drips at lower doses are well tolerated by nearly all members. Faster drips produce flushing, nausea, and mild chest discomfort that is uncomfortable but self-limiting. Pre-existing cardiovascular disease deserves a pre-infusion clearance from a member's cardiologist. Active malignancy is a relative contraindication, given that NAD+ supports cellular metabolism in ways that may be unwelcome in tumor tissue. Pregnancy is a contraindication.
The methylation-cofactor depletion that occurs during NAD+ metabolism is a less discussed concern. NAD+ catabolism produces nicotinamide, which is methylated and excreted; high doses of NAD+ can transiently lower SAMe and produce homocysteine elevations that we monitor on the bloodwork before and after. Members on the protocol have their methylation status checked at intake, and methyl donors (folate, B12, choline, betaine) are titrated alongside the infusion when indicated.
The honest framing
NAD+ is a real molecule with a real role in cellular metabolism, and a careful supplementation strategy — oral precursors at sustained daily doses, with occasional IV in narrowly indicated populations — is one of the more interesting positions in current longevity practice. It is not a flagship intervention. It is not a dramatic intervention. It is, when used with discipline, a modest one with a defensible mechanistic story.
Members who come in asking for "the NAD+ drip" usually leave with a longer conversation about what they are actually solving for. Sometimes the answer is the infusion. Often the answer is sleep. The discipline is keeping the question open until the data tells us which.
— Published in The Bioneer, Journal.